Availability and affordability of treatment for Human African Trypanosomiasis.
AffiliationMédecins Sans Frontières, 8 Rue Saint Sabin, Paris.
MetadataShow full item record
AbstractHuman African Trypanosomiasis (HAT) is a re-emerging disease whose usual treatments are becoming less efficient because of the increasing parasite resistance. Availability of HAT drugs is poor and their production in danger because of technical, ecological and economic constraints. In view of this dramatic situation, a network involving experts from NGOs, WHO and pharmaceutical producers was commissioned with updating estimates of need for each HAT drug for the coming years; negotiations with potential producers of new drugs such as eflornithine; securing sustainable manufacturing of existing drugs; clinical research into new combinations of these drugs for first and second-line treatments; centralizing drug purchases and their distribution through a unique non-profit entity; and addressing regulatory and legal issues concerning new drugs.
- Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis.
- Authors: Simarro PP, Franco J, Diarra A, Postigo JA, Jannin J
- Issue date: 2012 Jun
- [The return of sleeping sickness in an epidemic form: international action for drugs].
- Authors: Kager PA
- Issue date: 2002 Dec 28
- Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola.
- Authors: Robays J, Raguenaud ME, Josenando T, Boelaert M
- Issue date: 2008 Feb
- Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis.
- Authors: Nok AJ
- Issue date: 2003 May
- Production of sleeping-sickness treatment.
- Authors: Pécoul B, Gastellu M
- Issue date: 1999 Sep 11